Delaware BioScience Association President Bob Dayton and BIO President and CEO Jim Greenwood in this letter to the editor call on Delaware's lawmakers to protect consumer safety and ensure innovation of biosimilars as Congress works on health care reform legislation. Creating an avenue for regulatory approval will ensure biosimilars "are tested for safety while expanding access, lowering costs through expanded competition and providing incentives for biotech companies to continue innovating," they write.

Related Summaries